Pharmaceutical

Coya stretches lead drug’s development to Parkinson’s and dementia

Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.

Jan 17, 2024 - 18:00
Coya stretches lead drug’s development to Parkinson’s and dementia
Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.
Read the original article

Tags:

Previous Article

Bupa is leveraging its unique position to develop IoT and AI features

Next Article

US PTO voids Seagen’s ADC patent infringement claims against Daiichi

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT Morning Rounds: Six health news stories you need to start your day

STAT Morning Rounds: Six health news stories you need t...

Dec 5, 2023

Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’t hold up to scrutiny

Vivek Ramaswamy wants to ‘gut’ the FDA. His claims don’...

Aug 1, 2023

UnitedHealth faces class action lawsuit over algorithmic care denials in Medicare Advantage plans

UnitedHealth faces class action lawsuit over algorithmi...

Nov 15, 2023